News briefing: Biogen gets a quick date with an FDA panel for controversial aducanumab; Abeona CEO, board members exit — shares implode
Mark your calendars for November 6, which looms as the next major test for Biogen’s aducanumab. That’s the day the FDA has set aside for a panel review of the drug, which will be preceded by an in-house report on the pros and cons of the controversial drug.
The big biotech $BIIB gained steam on the news that the FDA had offered a priority review for the Alzheimer’s drug, which succeeded in one late-stage study and failed in another, only to be resurrected on the basis of some deep dives into subgroup data.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.